Frontier Biotechnologies Inc. (SHA:688221)
China
· Delayed Price · Currency is CNY 8.52
-0.12 (-1.39%)
At close: Apr 25, 2025, 2:57 PM CST
Frontier Biotechnologies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 129.47 | 110.42 | 83.4 | 40.47 | 46.37 | Upgrade
|
| Other Revenue | - | 3.83 | 1.34 | 0.03 | 0.25 | Upgrade
|
| Revenue | 129.47 | 114.25 | 84.74 | 40.5 | 46.62 | Upgrade
|
| Revenue Growth (YoY) | 13.33% | 34.82% | 109.22% | -13.13% | 123.50% | Upgrade
|
| Cost of Revenue | - | 81.13 | 69.35 | 49.71 | 42.5 | Upgrade
|
| Gross Profit | 129.47 | 33.12 | 15.39 | -9.21 | 4.12 | Upgrade
|
| Selling, General & Admin | - | 159.52 | 135.04 | 136.81 | 109.4 | Upgrade
|
| Research & Development | - | 214.23 | 274.33 | 172.11 | 138.49 | Upgrade
|
| Other Operating Expenses | 330.7 | 3.17 | 2.98 | 1.98 | 1.48 | Upgrade
|
| Operating Expenses | 330.7 | 377.34 | 413.94 | 312.12 | 249.77 | Upgrade
|
| Operating Income | -201.23 | -344.22 | -398.56 | -321.33 | -245.65 | Upgrade
|
| Interest Expense | - | -8.47 | -4.75 | -1.53 | -1.36 | Upgrade
|
| Interest & Investment Income | - | 23.51 | 25.9 | 44.3 | 7.37 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -3.58 | 0.68 | 0.09 | -0.62 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.29 | -0.91 | -2.03 | -0.48 | -0.55 | Upgrade
|
| EBT Excluding Unusual Items | -201.52 | -333.66 | -378.75 | -278.96 | -240.81 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -1.06 | -0.25 | 0.72 | 1.27 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -3.08 | -0.01 | 0 | -0 | Upgrade
|
| Asset Writedown | - | -3.22 | - | - | - | Upgrade
|
| Other Unusual Items | - | 12.05 | 22.25 | 12.97 | 4.02 | Upgrade
|
| Pretax Income | -201.52 | -328.96 | -356.76 | -265.27 | -235.52 | Upgrade
|
| Earnings From Continuing Operations | -201.52 | -328.96 | -356.76 | -265.27 | -235.52 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 5.21 | 4.79 | Upgrade
|
| Net Income | -201.52 | -328.96 | -356.76 | -260.06 | -230.73 | Upgrade
|
| Net Income to Common | -201.52 | -328.96 | -356.76 | -260.06 | -230.73 | Upgrade
|
| Shares Outstanding (Basic) | 373 | 374 | 364 | 361 | 288 | Upgrade
|
| Shares Outstanding (Diluted) | 373 | 374 | 364 | 361 | 288 | Upgrade
|
| Shares Change (YoY) | -0.17% | 2.69% | 0.79% | 25.23% | 9.40% | Upgrade
|
| EPS (Basic) | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 | Upgrade
|
| EPS (Diluted) | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 | Upgrade
|
| Free Cash Flow | - | -396.52 | -429.42 | -570.22 | -356.59 | Upgrade
|
| Free Cash Flow Per Share | - | -1.06 | -1.18 | -1.58 | -1.24 | Upgrade
|
| Gross Margin | 100.00% | 28.99% | 18.16% | -22.74% | 8.85% | Upgrade
|
| Operating Margin | -155.42% | -301.28% | -470.32% | -793.34% | -526.88% | Upgrade
|
| Profit Margin | -155.64% | -287.94% | -421.01% | -642.07% | -494.89% | Upgrade
|
| Free Cash Flow Margin | - | -347.07% | -506.74% | -1407.84% | -764.83% | Upgrade
|
| EBITDA | -177.65 | -320.64 | -352.29 | -283.37 | -207.46 | Upgrade
|
| EBITDA Margin | -137.21% | -280.65% | - | - | - | Upgrade
|
| D&A For EBITDA | 23.58 | 23.58 | 46.27 | 37.96 | 38.19 | Upgrade
|
| EBIT | -201.23 | -344.22 | -398.56 | -321.33 | -245.65 | Upgrade
|
| EBIT Margin | -155.42% | - | - | - | - | Upgrade
|
| Revenue as Reported | - | 114.25 | 84.74 | 40.5 | 46.62 | Upgrade
|
| Advertising Expenses | - | 0.31 | 0.09 | 1.13 | 0.81 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.